<DOC>
	<DOCNO>NCT02216266</DOCNO>
	<brief_summary>Evaluation physostigmine reduces symptoms patient develop delirium Intensive care surgery</brief_summary>
	<brief_title>Evaluation Physostigmine Reduces Symptoms Patients Who Has Developed Delirium Intensive Care After Surgery</brief_title>
	<detailed_description />
	<mesh_term>Emergencies</mesh_term>
	<mesh_term>Delirium</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Physostigmine</mesh_term>
	<criteria>Patients gender age &gt; 18 year , &lt; 85 year ICU C1 elective emergency heart surgery without extracorporeal circulation ( heartlung machine and/or extracorporeal membrane oxygenation ) , suspect delirium . ( May suspect patient show adequate improvement vigilance 24 h adequate reduction stop sedative medicine ) Patients ( &gt; 18a , &lt; 85a ) CAMICU diagnose delirium Patients legal capacity patient appoint representative Asthma hypersensitivity Physostigmine salicylate , Sodium metabisulfite , Nitrogen gangrene mechanical obstipation mechanical urinary retention Dystrophia myotonica Depolarization block depolarise muscle relaxant Intoxications `` irreversibly act '' cholinesterase inhibitor close head trauma obstruction gastrointestinal tract urinary tract neurological disease leave ventricular ejection fraction &lt; 40 % Simultaneous Participation clinical trial participation ind clinical trial last 30 day untreated coronary heart disease wish child , pregnancy nursing patient addictive disorder medical history</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Delirium</keyword>
	<keyword>CAM-ICU</keyword>
</DOC>